The major determinants of resistance to venetoclax in MCL and CLL patients have been identified as the overexpression and de novo synthesis of BCL-XL and MCL-1, antiapoptotic proteins belonging to the BCL2 family (20). Here, MCL1 is linked to mantle cell lymphoma.